GlassScriptPhysician profile
Michelle Mc Starke
NPI 1457337271
$3,527.55
in general payments reported to CMS, 2019-2025
27 companies · $570 in 2025
The $570 reported for 2025 was more than what 78% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $382 · 2021: $350 · 2022: $364 · 2023: $719 · 2024: $393 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.08 |
| Education | $183.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.28 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $598.95 | 2021-2025 | |
| Astellas Pharma US INC | $489.17 | 2023-2025 | Veozah, Myrbetriq |
| Vertical Pharmaceuticals, LLC | $248.44 | 2019-2020 | |
| Therapeuticsmd, INC. | $247.20 | 2019-2022 | |
| Millicent US INC | $127.29 | 2019-2025 | Femring, Intrarosa |
| Novo Nordisk INC | $125.66 | 2019-2025 | Wegovy |
| Exact Sciences Corporation | $120.01 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Coopersurgical, INC. | $115.63 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $111.94 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $93.34 | 2019-2020 | |
| Evofem Biosciences, INC. | $88.81 | 2024-2025 | Solosec, Phexx, Phexxi |
| Myovant Sciences INC. | $82.34 | 2021-2022 | |
| Acella Pharmaceuticals, LLC | $66.07 | 2023-2025 | NP Thyroid 60 |
| Allergan, INC. | $57.69 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $53.20 | 2020-2021 | |
| Mylan Pharmaceuticals INC. | $49.37 | 2020-2022 | |
| Mycovia Pharmaceuticals, INC. | $30.71 | 2023 | Vivjoa |
| Bayer Healthcare Pharmaceuticals INC. | $25.33 | 2025 | |
| Scynexis, INC. | $19.15 | 2022 | |
| Ibsa Pharma INC. | $17.36 | 2022 | |
| Virtus Pharmaceuticals LLC | $16.58 | 2022 | |
| Lupin INC. | $16.03 | 2021 | |
| Merck Sharp & Dohme LLC | $15.77 | 2020 | |
| Lilly USA, LLC | $14.84 | 2025 | Zepbound, Mounjaro |
| Duchesnay USA Incorporated | $12.36 | 2019 | |
| Avion Pharmaceuticals | $12.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Starke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.